Edgestream Partners L.P. acquired a new position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 4,890 shares of the medical research company’s stock, valued at approximately $1,443,000.
Several other large investors have also modified their holdings of the business. Bank of America Corp DE raised its holdings in shares of Charles River Laboratories International by 5.0% in the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock worth $195,792,000 after buying an additional 54,500 shares during the period. Aberdeen Group plc lifted its stake in shares of Charles River Laboratories International by 483.6% during the 3rd quarter. Aberdeen Group plc now owns 792,576 shares of the medical research company’s stock worth $233,818,000 after acquiring an additional 656,777 shares during the last quarter. Amundi boosted its holdings in Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after acquiring an additional 492,301 shares during the period. Russell Investments Group Ltd. boosted its holdings in Charles River Laboratories International by 457.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 436,055 shares of the medical research company’s stock valued at $128,641,000 after acquiring an additional 357,817 shares during the period. Finally, Danske Bank A S boosted its holdings in Charles River Laboratories International by 308,855.0% during the 3rd quarter. Danske Bank A S now owns 308,955 shares of the medical research company’s stock valued at $91,145,000 after acquiring an additional 308,855 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.
Analyst Ratings Changes
Several brokerages have commented on CRL. Barclays upped their price objective on Charles River Laboratories International from $330.00 to $375.00 and gave the company an “overweight” rating in a research report on Thursday, November 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Charles River Laboratories International in a research report on Monday, September 28th. Jefferies Financial Group boosted their target price on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the company a “buy” rating in a research note on Monday, September 28th. Zacks Research lowered shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 2nd. Finally, TD Cowen restated a “buy” rating and issued a $388.00 price target on shares of Charles River Laboratories International in a report on Wednesday, November 11th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $311.67.
Charles River Laboratories International Trading Down 4.2%
NYSE:CRL opened at $314.29 on Friday. Charles River Laboratories International, Inc. has a one year low of $146.20 and a one year high of $379.63. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.12 and a current ratio of 1.41. The firm has a market cap of $15.06 billion, a P/E ratio of 345.37, a P/E/G ratio of 2.84 and a beta of 1.36. The firm has a 50-day simple moving average of $316.09 and a 200-day simple moving average of $231.19.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.97 by $0.12. The firm had revenue of $982.73 million for the quarter, compared to the consensus estimate of $960.36 million. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The company’s quarterly revenue was down 2.2% on a year-over-year basis. During the same period last year, the firm earned $2.43 earnings per share. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.45 EPS for the current fiscal year.
Insider Buying and Selling at Charles River Laboratories International
In related news, Director James Foster sold 24,042 shares of the company’s stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $350.00, for a total transaction of $8,414,700.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at $11,058,600. This represents a 43.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon M. Parisotto sold 2,156 shares of the firm’s stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total value of $742,547.96. Following the sale, the executive vice president directly owned 4,807 shares in the company, valued at approximately $1,655,578.87. The trade was a 30.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 60,740 shares of company stock worth $19,528,128 in the last ninety days. Insiders own 1.30% of the company’s stock.
Charles River Laboratories International Profile
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
Further Reading
- Five stocks we like better than Charles River Laboratories International
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
